March 30, 2023

CRO CATAWBA RESEARCH NAMES ANDREW SILVERMAN, PH.D., AS COO

CHARLOTTE, N.C.; March 30, 2023 – Catawba Research, a full-service contract research organization (CRO) for innovative trial management, is delighted to announce Andy Silverman, Ph.D., has joined its leadership team as its chief operating officer (COO). 

Dr. Silverman joins a leadership team with more than 100 years of clinical research experience and an expansive and evolving portfolio of therapeutic success. Andy will be an active part of a dedicated management team that provides executive-level insights that guarantee protocol compliance and keep every component of a project on track. Dr. Silverman has 30+ years of deep clinical trial and executive experience within the CRO space, most recently as executive vice president, global operations at Syneos Health. Prior to his global role, Andy held several executive roles across the CNS division at INC Research (now Syneos) for over 15 years.  Dr. Silverman was the co-founder and COO of startup CRO, Tanistry, and associate director at both PPD and Pharmaco.  

“Dr. Silverman brings an immense level of specialized expertise that will help unlock new possibilities in trial management and health care,” said Catawba President & CEO Zaidoon A. Al-Zubaidy . “As our therapeutic portfolio is still growing, he’ll bring insights that leverage our track record of success in dermatology and women’s health into more recent triumphs in pulmonary, autoimmune and neurology research, all while continuing to ensure our clinical trials finish on time, on budget and with exemplary quality. Catawba Research is a place that cares about people — we cannot do what we do without positive leadership and a team of experts that take on challenges of clinical trials.”

About Catawba Research 
Catawba Research is a full-service contract research organization (CRO) with a passion for providing innovative trial management to pharmaceutical, device, formulation development and biotechnology companies. Founded in 2014, Catawba has over 100 years of combined C-suite leadership experience and an expansive and evolving portfolio of therapeutic success. More agile and cost-conscious than your average CRO, Catawba utilizes consistent scientific engagement and fiscally responsible planning to stay on time and on budget. In fact, while only 20% of clinical trials finish on time, 70% of all clinical trials partnered with Catawba Research either meet or exceed timeline objectives.  

Won’t you get hip to this kindly tip, get your kicks on Route 505(b)(2). What is that?Route 505(b)(2) vs. 505(j)Altasciences Acquires WCCT Global“ This acquisition is an integral part of Altasciences’ strategic growth plan to provide a comprehensive, fully integrated early phase drug development solution to address the ever-changing outsourcing challenges of biopAn Overview of GDUFAThe Office of Generic Drugs (OGD) reports directly to the Director of the Center for Drug Evaluation and Research (CDER). The OGD’s mission is to ensure safe, effective, and affordable medicines for the American public.Catawba Research Concludes Another Rosacea Clinical TrialCatawba Research is pleased to announce another achievement for a recently completed rosacea clinical trial. In this trial, Catawba enrolled more than 1000 rosacea subjects in 22 weeks from 33 sites .Catawba Research Achieves Acne First-to-FileThe team at Catawba Research has recently completed a first-to-file submission for acne clinical trial . In this study, Catawba enrolled a staggering 1125 acne vulgaris subjects in 8 weeks from 12 sites .Catawba Research Adds Tinea Pedis Video to Training LibraryTo learn more about our training program or see some our videos, contact us !